Better survival in female patients with hepatocellular carcinoma: Oral contraceptive pills related?

Journal of Clinical Gastroenterology

Volumn 39, Issue 6, 2005, Pages 533-539

  Lam, Chi Ming ^a   Yong, Jamy L ^a   Chan, Annie O ^a   Ng, Kelvin K ^a   Poon, Ronnie T ^a   Liu, Chi Leung ^a   Lo, Chung Mau ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Female patient; Gender; Hepatocellular carcinoma; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; OCTREOTIDE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADULT; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CIGARETTE SMOKING; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SEX RATIO; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CONTRACEPTIVES, ORAL; FEMALE; HONG KONG; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 20844460628     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000165670.25272.46     Document Type: Article

References (23)

1. Cong WM, Wu MC, Zhang XH, et al. Primary hepatocellular carcinoma in women of mainland China: a clinicopathologic analysis of 104 patients. Cancer. 1993;71:2941-2945.
2. Dohmen K, Shigematsu H, Irie K, et al. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18: 267-272.
3. Tangkijvanich P, Mahachai V, Suwangool P, et al. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:1547-1550.
4. Lee CC, Chau GY, Lui WY, et al. Better post-resectional survival in female cirrhotic patients with hepatocellular carcinoma. Hepatogastroenterology. 2000;47:446-449.
5. Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol. 1997;92:1355-1358.
6. Ng IO, Ng MM, Lai EC, et al. Better survival in female patients with hepatocellular carcinoma: possible causes from a pathologic approach. Cancer. 1995;75:18-22.
7. Nagasue N, Galizia G, Yukaya H, et al. Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology. 1989;36:379-383.
8. Yu L, Nagasue N, Yamaguchi M, et al. Effects of castration and androgen replacement on tumor growth of human hepatocellular carcinoma in nude mice. J Hepatol. 1996;25:362-369.
9. Matsumoto T, Takagi H, Mori M. Androgen dependency of hepatocarcinogenesis in TGFalpha transgenic mice. Liver. 2000;20:228-233.
10. Chen WT, Chau GY, Lui WY, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol. 2004;30:414420.
11. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am. 2003;12:35-50. viii.
12. Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001;88:515-522.
13. Calvet X, Bruix J, Gines P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990;12:753-760.
14. Akashi Y, Koreeda C, Enomoto S, et al. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology. 1991;14:262-268.
15. Liver including intrahepatic bile ducts. In: Greene FL, Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual, 6th ed. New York: Springer, 2002:131-144.
16. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63-70.
17. Evans AA, Chen G, Ross EA, et al. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002; 11:369-376.
18. Tarao K, Ohkawa S, Shimizu A, et al. The male preponderance in incidence of hepatocellular carcinoma in cirrhotic patients may depend on the higher DNA synthetic activity of cirrhotic tissue in men. Cancer. 1993;72:369-374.
19. Mucci LA, Kuper HE, Tamimi R, et al. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. Br J Obstet Gynaecol. 2001;108:291-294.
20. Yu MW, Cheng SW, Lin MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92:2023-2028.
21. Shen L, Ahuja N, Shen Y, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 2002; 94:755-761.
22. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res. 1995;55:498-500.
23. Chan AO, Peng JZ, Lam SK, et al. Reversal of E-cadherin promoter hypermethylation status after Helicobacter pylori eradication: implication in gastric cancer chemoprevention. AGA Distinguished Abstract Plenary Session, GI Oncology Plenary Session: Frontiers of Clinical Medicine and Translational Research, Digestive Disease Week, New Orleans, May 2004.